The personalized mRNA vaccine Intismeran from Moderna showed promising results in a clinical trial, reducing the risk of recurrence and spread of melanoma when administered alongside Merck's Keytruda immunotherapy, and interim data indicate successful achievements in the primary goals of the study. (translated)
Персонализирана иРНК ваксина показа обещаващи резултати срещу рак на кожата
